BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 12237244)

  • 1. Androgen receptors in prostate cancer.
    Culig Z; Klocker H; Bartsch G; Hobisch A
    Endocr Relat Cancer; 2002 Sep; 9(3):155-70. PubMed ID: 12237244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiandrogens in prostate cancer endocrine therapy.
    Culig Z; Bartsch G; Hobisch A
    Curr Cancer Drug Targets; 2004 Aug; 4(5):455-61. PubMed ID: 15320720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen axis in prostate cancer.
    Culig Z; Bartsch G
    J Cell Biochem; 2006 Oct; 99(2):373-81. PubMed ID: 16598769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Androgen receptor mutations in carcinoma of the prostate: significance for endocrine therapy.
    Culig Z; Klocker H; Bartsch G; Hobisch A
    Am J Pharmacogenomics; 2001; 1(4):241-9. PubMed ID: 12083956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours.
    Culig Z; Steiner H; Bartsch G; Hobisch A
    Endocr Relat Cancer; 2005 Jun; 12(2):229-44. PubMed ID: 15947099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
    Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
    Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression and function of androgen receptor coactivators in prostate cancer.
    Culig Z; Comuzzi B; Steiner H; Bartsch G; Hobisch A
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):265-71. PubMed ID: 15663989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquisition of agonistic properties of nonsteroidal antiandrogens after treatment with oncostatin M in prostate cancer cells.
    Godoy-Tundidor S; Hobisch A; Pfeil K; Bartsch G; Culig Z
    Clin Cancer Res; 2002 Jul; 8(7):2356-61. PubMed ID: 12114440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides.
    Eder IE; Culig Z; Ramoner R; Thurnher M; Putz T; Nessler-Menardi C; Tiefenthaler M; Bartsch G; Klocker H
    Cancer Gene Ther; 2000 Jul; 7(7):997-1007. PubMed ID: 10917202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential induction of androgen receptor transactivation by different androgen receptor coactivators in human prostate cancer DU145 cells.
    Yeh S; Kang HY; Miyamoto H; Nishimura K; Chang HC; Ting HJ; Rahman M; Lin HK; Fujimoto N; Hu YC; Mizokami A; Huang KE; Chang C
    Endocrine; 1999 Oct; 11(2):195-202. PubMed ID: 10709768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Androgen receptor in prostate cancer.
    Heinlein CA; Chang C
    Endocr Rev; 2004 Apr; 25(2):276-308. PubMed ID: 15082523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth.
    Culig Z; Bartsch G; Hobisch A
    Mol Cell Endocrinol; 2002 Nov; 197(1-2):231-8. PubMed ID: 12431817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Androgens up-regulate the insulin-like growth factor-I receptor in prostate cancer cells.
    Pandini G; Mineo R; Frasca F; Roberts CT; Marcelli M; Vigneri R; Belfiore A
    Cancer Res; 2005 Mar; 65(5):1849-57. PubMed ID: 15753383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells.
    Yeh S; Lin HK; Kang HY; Thin TH; Lin MF; Chang C
    Proc Natl Acad Sci U S A; 1999 May; 96(10):5458-63. PubMed ID: 10318905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen receptor signaling in prostate cancer.
    Culig Z; Santer FR
    Cancer Metastasis Rev; 2014 Sep; 33(2-3):413-27. PubMed ID: 24384911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptors in prostate cancer.
    Culig Z; Klocker H; Bartsch G; Steiner H; Hobisch A
    J Urol; 2003 Oct; 170(4 Pt 1):1363-9. PubMed ID: 14501770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.
    Liu Y; Majumder S; McCall W; Sartor CI; Mohler JL; Gregory CW; Earp HS; Whang YE
    Cancer Res; 2005 Apr; 65(8):3404-9. PubMed ID: 15833875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Androgen receptor--an update of mechanisms of action in prostate cancer.
    Culig Z; Hobisch A; Bartsch G; Klocker H
    Urol Res; 2000 Aug; 28(4):211-9. PubMed ID: 11011957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of mitogen-activated protein kinase pathway by the antiandrogen hydroxyflutamide in androgen receptor-negative prostate cancer cells.
    Lee YF; Lin WJ; Huang J; Messing EM; Chan FL; Wilding G; Chang C
    Cancer Res; 2002 Nov; 62(21):6039-44. PubMed ID: 12414626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular mechanisms involved in hormone resistance of prostate cancer].
    Cabrespine A; Guy L; Chollet P; Debiton E; Bay JO
    Bull Cancer; 2004 Oct; 91(10):747-57. PubMed ID: 15556875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.